Australian researchers warn GLP-1 weight-loss drugs may raise risk of scurvy, wounds ‘failing to heal’ properly

A recent systematic review conducted by Australian researchers has raised alarms regarding the potential health risks associated with GLP-1 weight-loss medications, commonly prescribed for diabetes and obesity management. The study highlights a significant gap in nutritional reporting in clinical trials for these drugs, suggesting that users may be at risk of developing nutrient deficiencies, including vitamin C deficiency, which can lead to conditions like scurvy. The researchers emphasize that these deficiencies could also impair wound healing, exacerbating health complications for individuals already managing chronic conditions. Given the increasing prevalence of obesity and diabetes in India and globally, the findings underline the necessity for comprehensive nutritional assessments in future drug trials. This will not only ensure patient safety but also enhance the efficacy of treatments aimed at weight loss and metabolic health. As health professionals and patients increasingly turn to GLP-1 medications, the implications of these findings could be significant, prompting calls for regulatory bodies to mandate thorough nutritional evaluations in clinical research.